Curriculum Vitae

Prof.Dr.Coskun Tecimer

Prof.Dr.Coskun Tecimer

Name Coşkun Tecimer
Place of Birth Kırşehir, Turkey
Date of Birth June 24, 1957
Present Address Gayrettepe Florence Nightingale Hospital, Gayrettepe / İstanbul
Tel (212) 2882476 Ext: 4184
Fax (212) 288 29 69
Current Position Professor and specialist in Internal Medicine and Hematology/Medical Oncology in Gayrettepe Florence Nightingale Hospital and İstanbul Science University, Faculty of Medicine, Turkey

PROFESSIONAL EXPERIENCE

INSTITUTION and LOCATION POSITION PERIOD  
Küre Health Station, Kastomonu, Turkey General Practitioner August 1981- March 1982  
Karamürsel Military Hospital, Kocaeli, Turkey Military physician
Military service
April 1982-August 1983  
Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey Resident in Medicine September 1983-November 1987  
Ministry of Education, Health Center, Ankara, Turkey Specialist in Internal Medicine February 1988-June 1991  
Inönü University, Faculty of Medicine, Department of Internal Medicine, Malatya, Turkey Assistant Professor of Medicine June 1991-October 1993  
Inönü University, Faculty of Medicine, Department of Internal Medicine, Malatya, Turkey Associate Professor of Medicine October 1993-October 1994  
Marmara University, Faculty of Medicine, Department of Internal Medicine, Division of Hematology / Immunology, İstanbul, Turkey Fellow in Hematology / Immunology October 1994-January 1996  
University of Louisville, Faculty of Medicine, Department of Internal Medicine, Division of Hematology/Medical Oncology, Louisville, Kentucky, USA Fellow in Hematology / Medical Oncology January 1996-January 1999  
Gayrettepe Florence Nightingale Hospital, Medical Oncology / Hematology, İstanbul, TURKEY Associate Professor in Medical Oncology / Hematology March 1999-June 2000  
Gayrettepe Florence Nightingale Hospital, Kadir Has University, Division of Internal Medicine, İstanbul, TURKEY Professor in Hematology / Medical Oncology Division of Internal Medicine June 2000-July 2004  
Gayrettepe Florence Nightingale Hospital, Medical Oncology / Hematology, İstanbul, TURKEY Professor in Medical Oncology / Hematology July 2004-August 2006  
Gayrettepe Florence Nightingale Hospital, İstanbul Science University, Medical Oncology Division, İstanbul,TURKEY Professor in Medical Oncology, Chief August 2006-August 2009  
Gayrettepe Florence Nightingale Hospital, Medical Oncology / Hematology, İstanbul, TURKEY Professor in Medical Oncology / Hematology August 2009-Present  
Gayrettepe Florence Nightingale Hospital, İstanbul Science University, Medical Oncology Division, İstanbul,TURKEY Professor in Medical Oncology / Hematology August 2012-Present  

PUBLICATIONS

1-Tecimer C, Oram Y, Tecimer T. Lupus vulgaris in a patient with pulmonary tuberculosis. Cutis 1994; 53:246-8.
2- Tecimer C, Yam LT. Surreptitious superwarfarin poisoning with brodifacoum. Southern Medical Journal 1997; 90:1053-5.
3-Tecimer C, Loy BA, Martin AW. Acute myeloblastic leukemia (M0) with an unusual chromosomal abnormality: Translocation (1;14) (p13;q32). Cancer Genetics and Cytogenetics 1999; 111:175-7.
4-Tecimer C, Doering D, Abdulhay G, Goldsmith J, Meyer JS, Wittliff JL. Clinical relevance of urokinase-type plasminogen activator, its receptor and inhibitor type 1 in ovarian cancer. International Journal of Gynecological Cancer 2000; 10:372-81.
5-Tecimer C, Doering D, Abdulhay G, Goldsmith J, Meyer JS, Wittliff JL. Clinical relevance of urokinase-type plasminogen activator, its receptor and inhibitor type 1 in endometrial cancer. Gynecologic Oncology 2001; 80:48-55.
6-Alço G, İğdem Ş, Dinçer M, Tecimer C, Şentürk R, Vural M, Okkan S. Gemcitabine induced radiation recall myositis: Report of two cases. International Journal of Hematology and Oncology 2009; 19: 249-253.
7-Akun E, Okutur K, Seber S, Korkmaz T, Aydın K, Bozkurt M, Namal E, Hasbal B, Tecimer C, Demir G. Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer. Journal of Balkan Union of Oncology 2012; 17: 669-76.
8-Pilancı KN, Elbüken F, Ordu Ç, Köksal G, Tekelioğlu MH, Okutur K, Göksel S, Köksal Ü, Akçal T, Tecimer C. A case of sunitinib induced hyperammonemic encephalopathy and hypothyroidism in metastatic renal cell carcinoma. American Journal of Theapeutics (in press)

PRESENTATIONS

1-Oto A, Tecimer C, Oram E, Uğurlu Ş, Karamehmetoğlu A, Oram A. Disturbance in the autonomic control of the heart rate in patients with acute myocardial infarction. Mediterranean Association of Cardiology and Cardiac Surgery 1st Annual Meeting, Cavtat-Dubrovnic Yugoslavia, October 8-11, 1987. Abstracts, 199.
2-Alpdoğan O, Budak-Alpdoğan T, Tanrıverdi S, Tecimer C, Fıratlı-Tuğlular T, Bayık M, Akoğlu T. The efficacy of mega-dose methylprednisolon treatment in patients with idiopathic thrombocytopenic purpura. The 13th Meeting of the International Society of Haematology (European and African Division), İstanbul, September 3-8, 1995. Abstract Book, Abstract No: 697.
3-Tecimer C, Bhupalam L, Djulbegovic B. Is standard heparin superior to low molecular weight heparin in malignancy related deep vein thrombosis? The 39th Annual Meeting of the American Society of Hematology, San Diego, CA, December 5-9, 1997. Blood 1997; 90: 124b.
4-Wittliff JL, Smolenkov AS, Tecimer C, Schmitt GA, Tuckson WB, Galandiuk S. Expression of urokinase-type plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1) in Russian and American patients with colon carcinoma. The Meeting of the Clinical Ligand Assay Society, New York, NY, Spring 1998. J Clin Ligand Assay 1998; 21: 87.
5-Tecimer C, Doering DL, Meyer JS, Abdulhay G, Goldsmith LJ, Wittliff JL. Prognostic significance of uPA, uPAR and PAI-1 expression in the management of endometrial cancer. The 35th Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, May 15-18, 1999. Proceedings 1999; 18: 160a.
6-Dane F, Yumuk PF, Turhal NS, Ekenel M, Başaran G, İyikesici MS, Tecimer C. FOLFOX 4 in metastatic colorectal cancer (MCRC) patients who progressed after infusional 5-FU/irinotecan based combination regimens. The 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, June 5-8, 2004. J Clin Onc, 2004; 22: 301S.
7-İğdem Ş, Altın M, Alço G, Ercan T, Kara B, Ünalan B, Tecimer C, Köksal G, Turkan S, Okkan S. PET/CT guided, dose painting IMRT for nasopharyngeal carcinoma. Proceedings of the American Society for Therapeutic Radiology and Oncology 50th Meeting, 21-25 September, 2008 Boston, MA. Radiation Oncology Biology, Physics 2008; 72: S424-5.
8-Okutur K, Turan C, Tecimer C, Demir G. Toxicity of bevacizumab (BV) in metastatic colorectal cancer (MCRC): Data from clinical practice. 7th Congress of B.U.O.N., 16-19 October, 2008, İzmir, Turkey. Journal of B.U.O.N. 2008; 13 (Suppl 1): S31.
9-Okutur K, Demir G, Tecimer C, Erdem L, Turan C. Toxicity of bevacizumab in metastatic colorectal cancer: Data from clinical practice. Poster presentation. 18th International Postgraduate Course of the International Association of Surgeons and Gastroenterologists and Oncologists, October 2008. Hepatogastroenterology Current Medical and Surgical Trends 2008; 55 (Suppl 1): S165-6.
10-Okutur K, Aydın K, Bozkurt M, Turan C, Demir N, Hasbal B, Erdem L, Tecimer C, Demir G. Toxicity of bevacizumab in metastatic colorectal cancer: Data from clinical practice. 1st Congress of the Mediterranean Multidisciplinary Oncology Forum, 10-13 September 2009, Athens. Abstract 28.
11-İğdem Ş, Altın M, Alço G, Ercan T, Ünalan B, Tecimer C, Köksal G, Gürses K, Demir G, Okkan S. Whole field simultaneous integrated boost IMRT in nasopharyngeal cancer. I J Radiation Oncology Biology Physics 2010; 78: S478.
12-Başaran G, Sağlam S, Tansan S, Demirel M, Gökmen E, Aktan S, Göker E, Kaban KK, Saip P, Demir G, Bavbek SE, Mandel NM, Tecimer C, Turhal NS, Garipoğlu M. The impact of 21-gene recurrence score (RS) scores on treatment decisions. Retrospective evaluation in Turkish early-stage breast cance (BC) patients. The 47th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 3-7, 2011. J Clin Onc, 2011; 29: Abstract No:e11042.
13-Bozkurt M, Okutur K, Aydın K, Namal E, Öztürk A, Tecimer C, Akçalı Z, Demir G. The impact of early thromboembolic event on prognosis in cancer patients: A single-center analysis of 1838 patients. The 47th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 3-7, 2011. J Clin Onc, 2011; 29: Abstract No:e19694.
14-Pilancı KN, Ordu Ç, Okutur K, İner Koksal Ü, Sağlam S, Tecimer C, Demir G. 17. European Cancer Congress, Amsterdam, 27 September-1 October 2013.
15-Alço G, İğdem Ş, Dinçer M, Özmen V, Demir G, Köksal G, Tecimer C, Selamoğlu D, Pilancı KN, Okkan S. Can megestrol acetate induce thrombosis in oncology patients? 17. European Cancer Congress, Amsterdam, 27 September-1 October 2013.

 
 
 

4830 Tüm Zamanlar 1 Bugün